 Syk inhibition has been proposed as a therapy for both lymphoma and chronic lymphocytic leukemia.Syk inhibitors are in clinical development, including cerdulatinib and entospletinib.Other inhibitors of B-cell receptor (BCR) signaling including ibrutinib (PCI-32765) which inhibits BTK, and idelalisib (PI3K inhibitor - CAL-101 / GS-1101) showed activity in the diseases as well.